Boston Scientific Corp. (BSX) is geared up for its landmark MADIT-CRT trial final results, which will be announced on Sept 1. The MADIT trial is evaluating the effectiveness of the company’s cardiac resynchronization therapy defibrillators (CRT-Ds), compared to the traditional implantable cardioverter defibrillators (ICDs). MADIT-CRT is the world’s largest randomized NYHA Class I/II CRT-D trial engulfing more than 1,800 asymptomatic or mildly symptomatic patients across 110 centers in 14 countries.
Preliminary results from this trial were published on June 23, which indicated that the trial met its primary objectives. Results demonstrated a 29% reduction in death or heart failure in patients implanted with CRT-Ds as compared to ICDs.
Positive final results will boost demand for Boston’s cardiac resynchronization therapy defibrillators, which will essentially drive the company’s top-line. Boston Scientific reported fiscal second quarter results with the cardiac rhythm management (CRM) segment registering revenue growth of 5% year over year. Within the CRM segment, ICD sales increased roughly 8% year over year to $454 million in the quarter.
Boston Scientific is a manufacturer of medical devices and products used in a broad range of interventional medical specialties. The company faces significant competition across its product portfolio. The primary competitors include Johnson & Johnson (JNJ), Medtronic Inc. (MDT), Abbott Laboratories (ABT) and St. Jude Medical Inc. (STJ). Based on the company’s performance, we have assigned a Neutral recommendation on the stock.

Read the full analyst report on “BSX”
Read the full analyst report on “JNJ”
Read the full analyst report on “MDT”
Read the full analyst report on “ABT”
Read the full analyst report on “STJ”
Zacks Investment Research